What is HepQuant?
HepQuant is dedicated to revolutionizing liver disease management through its proprietary non-invasive, blood-based quantitative tests. Their flagship product, HepQuant DuO, provides a crucial Disease Severity Index (DSI), empowering healthcare providers with actionable data for informed clinical decision-making. The company's solutions are designed to assist healthcare professionals, including clinicians and pharmaceutical developers, in effectively stratifying patient risk and managing chronic liver conditions. HepQuant's commitment to innovation drives the continuous advancement of their diagnostic tools, aiming to improve patient outcomes and streamline the approach to liver disease care.
How much funding has HepQuant raised?
HepQuant has raised a total of $341K across 2 funding rounds:
Debt
$150K
Debt
$191K
Debt (2020): $150K with participation from PPP
Debt (2021): $191K led by PPP
Key Investors in HepQuant
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for HepQuant?
With the recent influx of $191K in a major strategic investment, HepQuant is poised for accelerated growth and market penetration. This substantial capital infusion, contributing to the overall $341K in funding, will likely fuel the expansion of its commercial operations, further research and development into new diagnostic markers, and broader adoption of the HepQuant DuO system. The company's focus on late-stage, large-scale funding indicates a strategic move towards scaling its impact and solidifying its position as a leader in liver health diagnostics. Future endeavors may include strategic partnerships and further clinical validation to enhance its value proposition for both healthcare providers and patients.
See full HepQuant company page
